148 related articles for article (PubMed ID: 19018670)
1. Neutralization patterns and evolution of sequential HIV type 1 envelope sequences in HIV type 1 subtype B-infected drug-naive individuals.
Nyambi P; Burda S; Urbanski M; Heyndrickx L; Janssens W; Vanham G; Nadas A
AIDS Res Hum Retroviruses; 2008 Dec; 24(12):1507-19. PubMed ID: 19018670
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodies.
Haldar B; Burda S; Williams C; Heyndrickx L; Vanham G; Gorny MK; Nyambi P
PLoS One; 2011 Feb; 6(2):e17253. PubMed ID: 21383841
[TBL] [Abstract][Full Text] [Related]
3. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
[TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity.
Sagar M; Wu X; Lee S; Overbaugh J
J Virol; 2006 Oct; 80(19):9586-98. PubMed ID: 16973562
[TBL] [Abstract][Full Text] [Related]
5. Genetic and neutralization properties of HIV-1 env clones from subtype B/BC/AE infections in China.
Chong H; Hong K; Zhang C; Nie J; Song A; Kong W; Wang Y
J Acquir Immune Defic Syndr; 2008 Apr; 47(5):535-43. PubMed ID: 18209676
[TBL] [Abstract][Full Text] [Related]
6. Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies.
Rademeyer C; Moore PL; Taylor N; Martin DP; Choge IA; Gray ES; Sheppard HW; Gray C; Morris L; Williamson C;
Virology; 2007 Nov; 368(1):172-81. PubMed ID: 17632196
[TBL] [Abstract][Full Text] [Related]
7. Neutralization sensitivity of HIV-1 subtype B' clinical isolates from former plasma donors in China.
OuYang Y; Sun J; Huang Y; Lu L; Xu W; Hu X; Hong K; Jiang S; Shao Y; Ma L
Virol J; 2013 Jan; 10():10. PubMed ID: 23289760
[TBL] [Abstract][Full Text] [Related]
8. Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies.
Hogervorst E; de Jong J; van Wijk A; Bakker M; Valk M; Nara P; Goudsmit J
J Virol; 1995 Oct; 69(10):6342-51. PubMed ID: 7666535
[TBL] [Abstract][Full Text] [Related]
9. Glycans flanking the hypervariable connecting peptide between the A and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01_AE viruses.
O'Rourke SM; Sutthent R; Phung P; Mesa KA; Frigon NL; To B; Horthongkham N; Limoli K; Wrin T; Berman PW
PLoS One; 2015; 10(3):e0119608. PubMed ID: 25793890
[TBL] [Abstract][Full Text] [Related]
10. Mapping of Neutralizing Antibody Epitopes on the Envelope of Viruses Obtained from Plasma Samples Exhibiting Broad Cross-Clade Neutralization Potential Against HIV-1.
Cheedarla N; Sundaramurthi JC; Hemalatha B; Anangi B; Nesakumar M; Ashokkumar M; Vidya Vijayan KK; Tripathy SP; Swaminathan S; Vaniambadi SK; Ramanathan DV; Hanna LE
AIDS Res Hum Retroviruses; 2019 Feb; 35(2):169-184. PubMed ID: 30328700
[TBL] [Abstract][Full Text] [Related]
11. Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope.
Doria-Rose NA; Learn GH; Rodrigo AG; Nickle DC; Li F; Mahalanabis M; Hensel MT; McLaughlin S; Edmonson PF; Montefiori D; Barnett SW; Haigwood NL; Mullins JI
J Virol; 2005 Sep; 79(17):11214-24. PubMed ID: 16103173
[TBL] [Abstract][Full Text] [Related]
12. Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity.
Bradley T; Trama A; Tumba N; Gray E; Lu X; Madani N; Jahanbakhsh F; Eaton A; Xia SM; Parks R; Lloyd KE; Sutherland LL; Scearce RM; Bowman CM; Barnett S; Abdool-Karim SS; Boyd SD; Melillo B; Smith AB; Sodroski J; Kepler TB; Alam SM; Gao F; Bonsignori M; Liao HX; Moody MA; Montefiori D; Santra S; Morris L; Haynes BF
EBioMedicine; 2016 Oct; 12():196-207. PubMed ID: 27612593
[TBL] [Abstract][Full Text] [Related]
13. Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F.
Revilla A; Delgado E; Christian EC; Dalrymple J; Vega Y; Carrera C; González-Galeano M; Ocampo A; de Castro RO; Lezaún MJ; Rodríguez R; Mariño A; Ordóñez P; Cilla G; Cisterna R; Santamaría JM; Prieto S; Rakhmanova A; Vinogradova A; Ríos M; Pérez-Álvarez L; Nájera R; Montefiori DC; Seaman MS; Thomson MM
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):889-901. PubMed ID: 21226626
[TBL] [Abstract][Full Text] [Related]
14. Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.
Kothe DL; Decker JM; Li Y; Weng Z; Bibollet-Ruche F; Zammit KP; Salazar MG; Chen Y; Salazar-Gonzalez JF; Moldoveanu Z; Mestecky J; Gao F; Haynes BF; Shaw GM; Muldoon M; Korber BT; Hahn BH
Virology; 2007 Mar; 360(1):218-34. PubMed ID: 17097711
[TBL] [Abstract][Full Text] [Related]
15. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.
Li M; Salazar-Gonzalez JF; Derdeyn CA; Morris L; Williamson C; Robinson JE; Decker JM; Li Y; Salazar MG; Polonis VR; Mlisana K; Karim SA; Hong K; Greene KM; Bilska M; Zhou J; Allen S; Chomba E; Mulenga J; Vwalika C; Gao F; Zhang M; Korber BT; Hunter E; Hahn BH; Montefiori DC
J Virol; 2006 Dec; 80(23):11776-90. PubMed ID: 16971434
[TBL] [Abstract][Full Text] [Related]
16. Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response.
Laird ME; Igarashi T; Martin MA; Desrosiers RC
J Virol; 2008 Nov; 82(22):11054-65. PubMed ID: 18768967
[TBL] [Abstract][Full Text] [Related]
17. Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B.
Gray ES; Meyers T; Gray G; Montefiori DC; Morris L
PLoS Med; 2006 Jul; 3(7):e255. PubMed ID: 16834457
[TBL] [Abstract][Full Text] [Related]
18. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
[TBL] [Abstract][Full Text] [Related]
19. Structural Constraints at the Trimer Apex Stabilize the HIV-1 Envelope in a Closed, Antibody-Protected Conformation.
Guzzo C; Zhang P; Liu Q; Kwon AL; Uddin F; Wells AI; Schmeisser H; Cimbro R; Huang J; Doria-Rose N; Schmidt SD; Dolan MA; Connors M; Mascola JR; Lusso P
mBio; 2018 Dec; 9(6):. PubMed ID: 30538178
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain.
Lian Y; Srivastava I; Gómez-Román VR; Zur Megede J; Sun Y; Kan E; Hilt S; Engelbrecht S; Himathongkham S; Luciw PA; Otten G; Ulmer JB; Donnelly JJ; Rabussay D; Montefiori D; van Rensburg EJ; Barnett SW
J Virol; 2005 Nov; 79(21):13338-49. PubMed ID: 16227256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
